N,N-diethylaminoethyl bromide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N-diethylaminoethyl bromide
• 英文别名: bromoethyldiethylamine；1-bromo-N,N-diethylethanamine
• 化学式: C₆H₁₄BrN
• 分子量: 180.088
• InChiKey: KRIOYPGYOISJCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  四溴化碳 、 1-diethylamino-ethyl 以 乙腈 为溶剂， 生成 N,N-diethylaminoethyl bromide 、 tribromomethyl
  参考文献：
  名称：

  氨基烷基与烷基卤之间的卤素夺取反应：异常的高速率常数

  摘要：

  首次报道了氨基烷基自由基对卤素提取反应的极高反应活性。与CCl 4和CBr 4的反应速率常数接近扩散极限：它们比以前为典型烷基确定的常数高约4-5个数量级。使用分子轨道（MO）计算可以更好地理解这种异常行为。极性效应的参与是直接证据。这种方法对于设计新的还原剂可能很有用。

  DOI：

  10.1016/j.cplett.2008.02.052

文献信息

• Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists
  申请人：Bissantz Caterina

  公开号：US20070027173A1

  公开（公告）日：2007-02-01

  The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R 1 , R 2 and R 3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.

  本发明涉及作为V1a受体拮抗剂的吲哚-3-基-甲酰基-螺环-哌啶衍生物，其由公式I表示：其中，螺环-哌啶头基A以及残基R1、R2和R3如本文所述定义。本发明进一步涉及含有此类化合物的药物组合物，制备化合物和药物组合物的方法，以及它们在治疗痛经、高血压、慢性心力衰竭、血管升压素不适当分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁障碍中的用途。
• ACETYLSALICYLIC ACID DERIVATIVE CRYSTAL, ITS PREPARATION METHOD AND USE
  申请人：Zhejiang Yuejia Pharmaceuticals Co., Ltd

  公开号：US20180305296A1

  公开（公告）日：2018-10-25

  Disclosed are an acetylsalicylic acid derivative, i.e. a 2-(diethylamino)ethyl 2-acetoxy-benzoate hydrochloride crystal, and a preparation method and use thereof. The X-ray powder diffraction (XRPD) pattern of the crystal has characteristic peaks at the following 2θ angle: 11.0°±0.2°, 20.6°±0.2°, 25.1°±0.2°, 8.2°±0.2°, 16.5°±0.2°, 13.4°±0.2°, 25.4°±0.2°.

  公开了一种乙酰水杨酸衍生物，即2-(二乙氨基)乙基2-乙酰氧基苯甲酸盐酸盐晶体，及其制备方法和用途。该晶体的X射线粉末衍射(XRPD)图样在以下2θ角度具有特征峰：11.0°±0.2°, 20.6°±0.2°, 25.1°±0.2°, 8.2°±0.2°, 16.5°±0.2°, 13.4°±0.2°, 25.4°±0.2°。
• Therapeutic uses of PPAR mediators
  申请人：——

  公开号：US20030220373A1

  公开（公告）日：2003-11-27

  Use of PPAR mediators, and their pharmaceutical compositions, as ATP binding cassette transporter 1 (ABC-1) expression modulators, wherein the PPAR ligand receptor agonists of this invention are useful as inducers of ABC-1 expression.

  使用PPAR介质及其制药组合物作为ATP结合盒转运蛋白1（ABC-1）表达调节剂，本发明的PPAR配体受体激动剂可作为ABC-1表达的诱导剂。
• INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS
  申请人：Bissantz Caterina

  公开号：US20080146557A1

  公开（公告）日：2008-06-19

  The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R 1 , R 2 and R 3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.

  本发明涉及一种作为V1a受体拮抗剂的吲哚-3-基-羰基-螺-哌啶衍生物，其由式I表示：其中，螺-哌啶头基A和残基R1、R2和R3如本文所定义。本发明还涉及含有这种化合物的药物组合物、制备这种化合物和药物组合物的方法，以及它们在治疗痛经、高血压、慢性心力衰竭、抗利尿激素不适当分泌、肝硬化、肾病综合征、强迫症和焦虑抑郁症方面的用途。
• Organic Comopunds
  申请人：Collingwood Stephen Paul

  公开号：US20110201625A1

  公开（公告）日：2011-08-18

  A compound of Formula I or a hydrate or solvate thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  化合物I的配方或其水合物或溶剂化物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9和R10的含义如规范中所示，可用于治疗对上皮钠通道阻滞有反应的疾病。还描述了含有该化合物的制药组合物和制备该化合物的过程。